Why the study?
What are the pharmacokinetic properties of oral and intravenous amiodarone in healthy volunteers and patients with supraventricular tachycardia?
What are the pharmacokinetic properties of oral and intravenous amiodarone in healthy volunteers and patients with supraventricular tachycardia?
Amiodarone has a large volume of distribution, a long elimination half-life, and highly variable oral bioavailability, which informs its clinical dosing strategy.
Answers are grounded in this paper and cite their sources.
Supports monitoring amid variable bioavailability; extends PK data in SVT patients but leaves optimal regimens open.
We studied the kinetics of amiodarone in three healthy volunteers after single oral (400 mg) and intravenous (150 mg) doses and in six patients with supraventricular tachycardia. Three patients were studied after the first oral dose (400 mg) and during subsequent therapy (200 mg/day); the other three after 5 mg/kg of amiodarone intravenous. Blood was drawn at intervals for 24 h in patients and up to 32 h (i.v.) and 50 h (p.o.) from healthy volunteers. The drug was measured by high pressure liquid chromatography (HPLC). No difference in kinetic parameters was found between healthy subjects an patients. The pharmacokinetic parameters, calculated on the intravenous data using a two-compartment open model, indicate a very large volume of distribution (9.26-17.17 L/kg in healthy volunteers and 6.88-21.05 L/kg in patients). The elimination half-life ranged from 12.09 to 20.70 h in volunteers and from 11.60 to 19.60 h in patients. Oral absorption was slow an erratic, with fourfold individual variations in systemic bioavailability (22-86%). A slight accumulation of amiodarone was observed in patients under chronic treatment.
No takes yet. Share an insight, caveat, or question.
Riva et al. (1982) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: